Exact Sciences is demonstrating significant top-line momentum with 23.1% year-over-year revenue growth in 2025Q4, yet the firm remains challenged by a persistent inability to achieve operating leverage as SG&A expenses continue to outpace gross profit. While t...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 23.1% in 2025Q4, though the company continues to struggle with profitability as evidenced by a -9.4% operating margin.
Exact Sciences' collaboration with Walgreens integrates Cologuard into pharmacy workflows, increasing accessibility for average-risk customers.
The FDA-approved at-home colorectal cancer screening test is being promoted through nationwide initiatives, driving potential market penetration.
Pharmacist-led services for Cologuard requests aim to close care gaps, enhancing patient engagement and test utilization.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q1 2026Latest Feb 13, 2026 | -$0.45-316.9% vs -$0.11 | $878M+2.0% vs $861M |
Q4 2025 Nov 3, 2025 | $0.24+492.0% vs -$0.06 | $851M+5.0% vs $811M |
Q3 2025 Aug 6, 2025 | $0.22+1200.0% vs -$0.02 | $811M+0.1% vs $810M |
Q2 2025 May 1, 2025 | -$0.54-45.9% vs -$0.37 | $707M+2.6% vs $689M |
Abbott Laboratories NYSE: ABT gave the market what it wanted in its Q2 earnings report, affirming that the Exact Sciences acquisition was a good one. The critical takeaways are that comp growth is solid, the Exact Sciences business has traction, and the near-term margin impairment the acquisition brought is less than expected.
Abbott Laboratories is upgraded to Buy ahead of Q2 2026 earnings, following a challenging period marked by share price underperformance. The recent acquisition of Exact Sciences adds a high-growth cancer diagnostics vertical, targeting $3bn incremental 2026 sales and potential long-term revenue expansion. 2026 guidance projects 6.5–7.5% organic sales growth and $5.38–$5.58 adjusted EPS, with Exact Sciences acquisition causing $0.20 EPS dilution.
Benchmark EXAS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Exact Sciences Corporation (EXAS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $177.16 | $23.49B | -53.36 | 32.88% | -38.33% | — | — | |
| $390.90 | $55.98B | -257.17 | 35.9% | -7.11% | -11.73% | — | |
| $247.46 | $37.44B | 45.41 | -0.78% | 18.36% | 31.08% | — | |
| $311.54 | $25.55B | 29.78 | 7.25% | 6.99% | 11.55% | — | |
| $234.85 | $25.92B | 26.84 | 11.78% | 9.19% | 14.09% | — |
Exact Sciences Corporation (EXAS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Exact Sciences Corporation (EXAS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Mar 23, 2026·SEC
Mar 20, 2026·SEC
Feb 20, 2026·SEC
Get notified when EXAS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Exact Sciences Corporation (EXAS) stock FAQ — growth, dividends, profitability & financials explained
Exact Sciences Corporation (EXAS) reported $3.25B in revenue for fiscal year 2025.
Exact Sciences Corporation (EXAS) grew revenue by 17.7% over the past year. This is strong growth.
Exact Sciences Corporation (EXAS) reported a net loss of $207.9M for fiscal year 2025.
Exact Sciences Corporation (EXAS) has a return on equity (ROE) of -8.7%. Negative ROE indicates the company is unprofitable.
Exact Sciences Corporation (EXAS) generated $356.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
